Protara Therapeutics Inc. (TARA)
4.63
0.01 (0.22%)
At close: Mar 21, 2025, 3:00 PM
0.22% (1D)
| Bid | 4.63 |
| Market Cap | 170.23M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -76.4M |
| EPS (ttm) | -2.17 |
| PE Ratio (ttm) | -2.13 |
| Forward PE | -2.19 |
| Analyst | Buy |
| Ask | 5.61 |
| Volume | 139,680 |
| Avg. Volume (20D) | 303,832 |
| Open | 4.54 |
| Previous Close | 4.62 |
| Day's Range | 4.38 - 4.66 |
| 52-Week Range | 1.59 - 10.48 |
| Beta | 1.68 |
About TARA
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failur...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 22, 2014
Employees 28
Stock Exchange NASDAQ
Ticker Symbol TARA
Website https://www.protaratx.com
Analyst Forecast
According to 4 analyst ratings, the average rating for TARA stock is "Buy." The 12-month stock price forecast is $23, which is an increase of 396.76% from the latest price.
Stock Forecasts3 months ago
+70.06%
Protare Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
